Inchingolo Alessio Danilo, Malcangi Giuseppina, Ceci Sabino, Patano Assunta, Corriero Alberto, Azzollini Daniela, Marinelli Grazia, Coloccia Giovanni, Piras Fabio, Barile Giuseppe, Settanni Vito, Mancini Antonio, De Leonardis Nicole, Garofoli Grazia, Palmieri Giulia, Isacco Ciro Gargiulo, Rapone Biagio, Jones Megan, Bordea Ioana Roxana, Tartaglia Gianluca Martino, Scarano Antonio, Lorusso Felice, Macchia Luigi, Larocca Angela Maria Vittoria, Tafuri Silvio, Migliore Giovanni, Brienza Nicola, Dipalma Gianna, Inchingolo Francesco
Department of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Department of Interdisciplinary Medicine, Intensive Care Unit Section, Aldo Moro University, 70121 Bari, Italy.
Biomedicines. 2022 Sep 26;10(10):2402. doi: 10.3390/biomedicines10102402.
The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients' activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari "Aldo Moro" led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.
接种BNT162b2疫苗后IgG SARS-CoV-2抗刺突抗体的分泌及保护作用代表了人体对病毒载体有症状感染的反应。本研究的目的是评估巴里综合诊所医护人员的免疫反应，以确定抗刺突滴度与血型、性别、年龄和合并症之间的关系。这项前瞻性观察研究（复兴研究）的主要终点是评估在三个血滴度下对BNT162b2的血清学反应：第一个血滴度在第二剂接种后60天（2021年2月3日）；第二个血滴度在第一个血滴度后75天；第三个血滴度在第二剂接种后130天。在230名登记的工作人员中，所有人对辉瑞mRNA（BNT162b）疫苗反应良好。只有一名患者在第二剂接种后40天（2021年2月3日），于2021年3月15日进行的拭子检测呈阳性，尽管完全无症状，且在随后于2021年3月30日进行的分子拭子检测中呈阴性。在第一次抗刺突蛋白检测（2021年4月3日第二剂接种后60天）时，所有患者对辉瑞mRNA（BNT162b）疫苗的抗刺突IgG水平均高于500 BAU/mL；在第二个血滴度（2021年6月20日第一个血滴度后75天）时，4名（占登记的230人的1.7%）患者的抗刺突IgG水平低于500 BAU/mL；在第三个血滴度（2021年6月30日第二剂接种后130天，即第二剂接种后9个月）时，37名（占登记的230人的16.1%）患者的抗刺突IgG水平低于500 BAU/mL。数据分析表明，无论其恒河猴因子如何，0血型患者的抗体水平比其他组最强。未发现低抗体水平与性别或年龄之间存在相关性。每月15日持续进行分子拭子检测。然而，登记患者的活动处于高风险中，因为他们进行牙科和外科等医疗活动，以及涡轮机、压电手术产生的水蒸气飞沫。巴里大学“阿尔多·莫罗”综合诊所医护人员的疫苗接种活动导致了良好的血清学反应，且完全没有COVID-19事件病例，因此抗体反应良好。COVID-19疫苗加强针应在9个月后接种，且不应在未及时检测抗刺突滴度以评估该特定患者是否存在免疫力下降迹象的情况下接种。
